LumiThera
19332 Powder Hill Place NE
Poulsbo
Washington
98370
United States
About LumiThera
LumiThera is a clinical-stage medical device company focused on the use of photobiomodulation ("PBM"), using non-invasive light emitting diodes ("LED") to treat patients with acute and chronic ocular diseases and disorders. The Company is currently developing an ophthalmologist LED office-based instrument to be used in treating dry Age-related Macular Degeneration.
YEAR FOUNDED:
2013
LEADERSHIP:
Founders: Clark E. Tedford, Robert Dotson, Graham Merry, James Carroll, and Luis De Taboada
Founder and CEO: Clark E. Tedford
Founder and CMO: Robert Dotson
PRODUCTS: All Products
7 articles with LumiThera
-
LumiThera Announces a Distribution Agreement for the Valeda Light Delivery System with Miloftalmica in Italy
12/11/2018
LumiThera, Inc., announced a distribution agreement with Miloftalmica to exclusively distribute the Valeda™ Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in Italy.
-
LumiThera and Optos Announce Collaboration to Commercialize the Valeda™ Light Delivery System for Treating Dry Age-Related Macular Degeneration in Europe
10/24/2018
Optos is recognized as the leading provider of ultra-widefield retinal imaging devices to eyecare professionals for improved patient eye care.
-
LumiThera, Inc. Selected to Present at the Ophthalmology Innovation Summit 2018 at the American Academy of Ophthalmology, Chicago, IL
10/19/2018
LumiThera® Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, today announced that it will present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS@AAO) meeting on October 25, 2018, in Chicago, IL.
-
LumiThera LT-300 Device For Treating Dry Advanced Macular Degeneration Granted CE Mark
6/22/2018
The "CE" mark is the abbreviation for Conformité Européenne, meaning European Conformity.
-
LumiThera Presents LIGHTSITE I Dry AMD Top Line Final Data
5/1/2018
LumiThera Inc. presented topline final results from the LIGHTSITE I clinical trial for the treatment of dry age-related macular degeneration (AMD) utilizing its LT-300 Light Delivery System.
-
LumiThera Inc. to Present at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS)
3/13/2018
LumiThera Inc., a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announces that Clark E. Tedford, Ph.D., Chief Executive Officer, is scheduled to present on Saturday, March 17, 2018 at 9:30 a.m. China Standard Time, at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS) in Hangzhou, China.
-
LumiThera Unveils LIGHTSITE I Dry AMD Clinical Interim Data
11/7/2017
The 30-subject pilot study funded from a SBIR grant awarded to the Company from the NIH and the National Eye Institute is testing each subject's vision and examining disease pathology in the eye, following PBM treatments for up to one year.